Clinical Trial Update: Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the addition of M6620 (berzosertib; VX-970) to standard chemotherapy and radiation for head and neck cancers, including head and neck s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Carcinoma of Unknown Primary
• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Sinonasal Squamous Cell Carcinoma

Drugs mentioned

• M6620 (VX-970, Berzosertib) (berzosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-27